Novel chemotherapy combination of carfilzomib with dexamethasone, cyclophosphamide, etoposide and cisplatin (K-DCEP) for the treatment of relapsed/refractory aggressive plasma cell dyscrasias

MeSH terms

• Aged
• Antineoplastic Combined Chemotherapy Protocols* / adverse effects
• Antineoplastic Combined Chemotherapy Protocols* / therapeutic use
• Cisplatin* / administration & dosage
• Cisplatin* / adverse effects
• Cisplatin* / therapeutic use
• Cyclophosphamide* / administration & dosage
• Cyclophosphamide* / therapeutic use
• Dexamethasone* / administration & dosage
• Drug Resistance, Neoplasm
• Etoposide* / administration & dosage
• Female
• Humans
• Male
• Middle Aged
• Oligopeptides* / administration & dosage
• Paraproteinemias / diagnosis
• Paraproteinemias / drug therapy
• Recurrence
• Treatment Outcome